These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 18794651)

  • 1. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials.
    Kinon BJ; Ascher-Svanum H; Adams DH; Chen L
    J Clin Psychopharmacol; 2008 Oct; 28(5):544-9. PubMed ID: 18794651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
    Canuso CM; Bossie CA; Amatniek J; Turkoz I; Pandina G; Cornblatt B
    Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response.
    Reynolds GP; Yao Z; Zhang X; Sun J; Zhang Z
    Eur Neuropsychopharmacol; 2005 Mar; 15(2):143-51. PubMed ID: 15695058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
    Emsley R; Berwaerts J; Eerdekens M; Kramer M; Lane R; Lim P; Hough D; Palumbo J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):343-56. PubMed ID: 18854723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
    Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting risperidone improves negative symptoms in stable psychotic patients.
    Curtis VA; Katsafouros K; Möller HJ; Medori R; Sacchetti E
    J Psychopharmacol; 2008 May; 22(3):254-61. PubMed ID: 18308804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
    Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
    Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial.
    Berk M; Copolov D; Dean O; Lu K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Judd F; Katz F; Katz P; Ording-Jespersen S; Little J; Conus P; Cuenod M; Do KQ; Bush AI
    Biol Psychiatry; 2008 Sep; 64(5):361-8. PubMed ID: 18436195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
    Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
    J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials.
    Stauffer V; Case M; Kollack-Walker S; Ascher-Svanum H; Ball T; Kapur S; Kinon BJ
    Schizophr Res; 2011 Aug; 130(1-3):11-9. PubMed ID: 21489754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender-specific associations of depression with positive and negative symptoms in acute schizophrenia.
    Müller MJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1095-100. PubMed ID: 17493732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone in first-episode schizophrenia.
    Cesková E; Prikryl R; Kaspárek T
    Neuro Endocrinol Lett; 2007 Dec; 28(6):811-4. PubMed ID: 18063925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale.
    Levine SZ; Rabinowitz J
    J Clin Psychopharmacol; 2007 Oct; 27(5):431-6. PubMed ID: 17873671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of augmentation with moclobemide on symptoms of schizophrenia.
    Silver H; Aharon N; Hausfater N; Jahjah N
    Int Clin Psychopharmacol; 1999 May; 14(3):193-5. PubMed ID: 10435775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the use of the positive and negative syndrome scale-excited component as a criterion for administration of p.r.n. medication.
    Chaichan W
    J Psychiatr Pract; 2008 Mar; 14(2):105-13. PubMed ID: 18360196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.
    Berk M; Gama CS; Sundram S; Hustig H; Koopowitz L; D'Souza R; Malloy H; Rowland C; Monkhouse A; Monkhouse A; Bole F; Sathiyamoorthy S; Piskulic D; Dodd S
    Hum Psychopharmacol; 2009 Apr; 24(3):233-8. PubMed ID: 19330802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of the emotional blunting and its prognostic importance during neuroleptic treatment of schizophrenia].
    Kukulska D
    Psychiatr Pol; 2003; 37(6):999-1012. PubMed ID: 14727372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.